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Introduction 
Tuberculosis (TB), one of the oldest diseases 
known to affect humans, did not have an effective 
treatment until 1940-1950. The emergence of power- 
ful anti-tuberculosis drugs in the second half of this 
century, and the progressive decline in the incidence 
of TB, suggested that eradication of the disease was 
possible, at least in the developed world. 
The acquired immunodeficiency syndrome (AIDS) 
pandemic in the 1980s and the emergence of 
multidrug-resistant tuberculosis (MDRTB) in the last 
few years have shown that these expectations were 
too optimistic. Tuberculosis is far from being con- 
trolled and remains as much a major health problem 
at the end of the century as it was at the beginning 
(1). Today, one-third of the world population is 
infected with Mycobacterium tuberculosis, resulting in 
8 million new cases and 2.9 million deaths from TB 
yearly (2). 
This article provides an overview on the past, 
present, and future of chemotherapy for TB. 
Evolution of the Chemotherapy for Tuberculosis 
Table 1 shows the evolution of TB treatment in the 
last few decades, schematically. The modern chemo- 
therapeutic era began with the introduction of strep- 
tomycin @TM) in 1943. The most important advance 
in the treatment of TB took place with the intro- 
duction of isoniazid (INH) in 1952 (3). This drug, 
combined with STM and para-aminosalicilic acid 
(PAS) allowed the cure of more than 90% of patients, 
but the treatment period was very long. In the 196Os, 
ethambutol (EMB) was introduced to replace the 
poorly tolerated PAS and the treatment period was 
shortened. 
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The reported efficacy of rifampin (RIF) in 1971 (4) 
was a major breakthrough because the regimens that 
included this drug were able to cure virtually all 
patients with an important shortening of the treat- 
ment period. A 6-month period of treatment 
adequate to cure TB was established in the 1980s in 
several well controlled studies after the effectiveness 
of pyrazinamide (PZA) on intracellular bacilli was 
shown (5). 
Although the trend in the 1990s would have been 
to maintain both the number of drugs and the 
duration of treatment, the increasing experience with 
AIDS TB patients has suggested that an extended 
treatment (to 9 months, or 6 months after culture 
conversion to negative) is convenient in these patients 
(6,7). The emergence of MDRTB has led us to 
lengthen the treatment to 18 months or more, due to 
the lower efficacy of the drugs available for treatment 
of such cases (89). Therefore, although the situation 
is not as bad as it was half a century ago, we now face 
a problem that we believed to be overcome: the 
use, in some cases, of drugs of limited efficacy for 
prolonged periods of time. 
Current Treatment Regimens (10-16) 
Since the 1980s it has been evident that short 
courses of therapy are as effective as longer courses 
in pulmonary TB. Furthermore, the costs and late 
toxicity of the chemotherapy were reduced, and 
the possibility of patient’s adherence to treatment 
improved with the short courses. 
Today, the standard period of treatment for pul- 
monary TB in the absence of infection with human 
inmunodeficiency virus (HIV) or drug resistance is 
6 months. The most widely accepted regimen is the 
combination of INH, RIF, and PZA daily for 2 
months, followed by INH and RIF daily for 4 
additional months or, with appropriate dosage 
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Table I The evolution of anti-tuberculosis treatment 
Years Drugs used Length of treatment 
1940s STM -I- PAS 24 months 
1950s INH + STM + PAS 24 months 
1960s INH + STM + EMB 18 months 
1970s INH+RIF+EMB 9-12 months 
1980s INH+RIF+EMB+PZA 6 months 
1990s INH+RIF+PZA+? &? months 
? denotes additional drugs and time required for treatment 
of AIDS patients and multidrug-resistant tuberculosis. See 
text. 
adjustments, twice- or thrice-weekly. Ethambutol or 
STM should be added if resistance to INH is sus- 
pected. Another regimen combines four drugs (INH, 
RIF, PZA, and either EMB or STM) daily for the 
first 2 weeks followed by the same drugs twice-weekly 
for 6 weeks, and INH in combination with RIF 
twice-weekly for 4 additional months. Finally, 
another regimen consists of the same four drugs 
thrice-weekly for 6 months. 
Even shorter courses of 4 months are efficacious in 
cases of small mycobacterial burden as evidenced by 
studies carried out in Arkansas (17) and Hong Kohg 
(18) on smear-negative pulmonary TB. 
General Rules of the Anti-tuberculosis Therapy 
In general, the number of drugs required should 
increase as the number of bacilli found in lesions 
increases. Consequently, the number of drugs can be 
reduced when the bacillary burden is reduced. 
Although the emergence of resistance to the anti- 
tuberculosis drugs is a major problem today, the 
main cause of failure of the therapy is the lack of 
adherence to the treatment. Accordingly, every effort 
should be made to ensure compliance. 
Drug resistance should be suspected in several 
situations such as failure of treatment, unreliable 
patients, contact with patients known to have resis- 
tant strains, massive bacillary burden, homeless 
patients, immigrants from areas known to have 
resistance, and presence of positive cultures after 
3 months of therapy. In the case of confirmed or 
suspected resistance to drugs in patients who appar- 
ently are non-responders, a single drug should never 
be added to the treatment because development of 
resistance to the new agent is the rule. In this 
situation, at least two, but preferably three to five 
drugs to which resistance is known, or thought, not 
to exist, should be added. 
Mycohacterial Populations and Action of the Major 
Drugs 
Mitchison suggested that there are different popu- 
lations of bacilli with different rates of growth and 
drug susceptibilities (19). One population is in con- 
tinuous growth and replication. Isoniazid is the best 
drug to kill these bacilli, although both RIF and 
STM also appear to be useful. On the opposite side of 
the spectrum, there is a population composed of 
dormant organisms to which no drug appears to be 
active. The remaining two populations are intracellu- 
lar bacilli in an acid environment with slow growth 
rates susceptible to the action of PZA, and a popu- 
lation of mostly dormant organisms, which have 
intermittent spurts of metabolism. Rifampin would 
be the most effective drug against this population. 
The rate of killing of the bacilli is not constant 
throughout the entire period of treatment. This rate 
is fastest during the first 2 days and slower during the 
subsequent days and weeks (20). Accordingly, the 
first phase is known as the early bactericidal activity 
and the second phase is termed the sterilizing activity. 
Major anti-tuberculosis drugs can be classified 
according to their relative early bactericidal and 
sterilizing activities (21). Thus, INH is the best early 
bactericidal drug although its sterilizing activity is 
lower. Both RIF and PZA have a remarkable steril- 
izing activity, and in the case of RIF, a good early 
bactericidal activity. On the contrary, both STM and 
EMB have a good to intermediate early bactericidal 
activity and a poor sterilizing activity. 
Mechanisms of Action of the Major Anti-tuberculosis 
Drugs (10,22,23) 
The mechanism of action of INH appears to be the 
inhibition of an enzyme involved in the synthesis of 
mycolic acid, a long-chain fatty acid of the mycobac- 
terial cell wall essential for the integrity of the bacil- 
lus. Rifampin appears to act by interfering with 
transcription and RNA elongation by binding of the 
drug to the P-subunit of the DNA-dependent RNA 
polymerase. Pyrazinamide is especially active against 
bacilli in the intracellular, acidic environment 
through its conversion to the active metabolite, 
pyrazinoic acid. Ethambutol is a bacteriostatic drug 
active only against actively growing bacilli. The 
mechanism of action is not well known but probably 
involves impairment of RNA synthesis. Finally, 
STM, like other aminoglucosides, acts in the extra- 
cellular alkaline environment through the disruption 
of protein synthesis by irreversible binding to the 30s 
subunit of the mycobacterial ribosome. 
Topical Review 465 
Spontaneous Resistance to Anti-tuberculosis Drugs is 
Genetically Determined 
Theoretically all the bacilli derived from a single 
clone should have the same pattern of susceptibility 
to drugs as the original bacillus. However, the emer- 
gence of random chromosomal mutants results in 
organisms that are spontaneously resistant to a drug 
to which the original bacillus was susceptible. The 
mutant bacilli will give rise to a population of bacilli 
resistant to the same drug. These spontaneous muta- 
tions depend on the number of bacilli regardless of 
their localization, and their frequency is different for 
each drug: one mutation in 105-lo6 bacilli for INH, 
lo’-10’ for RIF, lo*-lo4 for PZA, 104-lo6 for EMB, 
105-lo6 for STM, and 103-lo6 for PAS (14,24-28). 
The rationale for the combination of several drugs 
in the treatment of TB is also based on these spon- 
taneous mutations. Thus, the probability that the 
progeny of a wild bacillus could become resistant to 
both INH and RIF is the result of the product of 
the individual probabilities, i.e. one mutation in 
lo’*-lOi bacilli. Similarly, the probability of resist- 
ance to INH, RIF, and PZA is one mutation in 
10’4-10’s bacilli. Keeping in mind that the number of 
bacilli in patients with cavitary TB is estimated to be 
between lo’-109, the use of a single drug will cer- 
tainly result in a resistant population with time. 
However, spontaneous resistance should not be a 
problem when two or three of these agents are used in 
combination, because the number of bacilli required 
to result in a spontaneously resistant bacillus is too 
large. 
Genetic Mechanisms of Drug Resistance 
Although the intimate mechanisms of resistance to 
the anti-tuberculosis drugs are largely unknown, 
recent investigations have resulted in a considerable 
advance in this field. 
The catalase-peroxidase activity is required for the 
action of INH. Deletions or mutations of the 
catalase-peroxidase gene (katG) are associated with 
INH-resistance, and transfer of the wild gene to 
resistant organisms confers susceptibility to the drug 
(29-31). However, only 24% of the isolates from New 
York City seem to lack katG sequences (32). Conse- 
quently, other factors must also be involved in the 
resistance to INH. 
Recently, a mis-sense mutation within the myco- 
bacterial inhA gene has been described that confers 
resistance to both INH and ethionamide (33). The 
product of this gene, the inhA protein, differs from 
the original protein by a single substitution of Ser to 
Ala at position 94. Mutations in this gene could 
account for the isolates resistant to INH with normal 
catalase activity. However, additional studies are 
necessary to elucidate whether mutations in genes 
other than katG and inhA can also confer resistance 
to INH. 
In the case of RIF, the molecular mechanism of 
resistance seems to be the substitution of a limited 
number of highly conserved amino acids encoded by 
the rpoB gene, the gene that encodes for the RNA 
polymerase B-subunit (34). The substitution of key 
amino acids would thus result in conformational 
changes of the p-subunit and defective binding of the 
drug. 
Finally, resistance of M. tuberculosis to STM 
appears to be mediated by mutations in the gene 
encoding for the 16s ribosomal RNA (35) as well as 
in the ribosomal S12 protein gene (36). 
MDRTB - Magnitude of the Problem 
Multidrug-resistant TB, the third epidemic (37) 
has emerged as a major public health concern in the 
last few years. Some authors consider MDRTB an 
iatrogenic phenomenon. Inappropriate control of 
treatment, reduced funding for the fight against TB, 
inadequate or antiquated tools and failure to effec- 
tively apply those available, neglected or ineffective 
control procedures, inadequate training of health- 
care workers, closure of facilities for managing TB 
patients, poverty, drug abuse, deterioration of the 
social conditions and of the public health infrastruc- 
ture, patients’ access to anti-tuberculosis drugs 
favouring inadequate regimens, and the epidemic of 
HIV infection, among others, are factors that have 
contributed to the development of MDRTB (38,39). 
Resistance to anti-tuberculosis drugs is not uni- 
formly distributed, being more prevalent in large 
urban areas. Thus, New York City has more than 
60% of all cases of MDRTB of the U.S. (40). In this 
city, the rate of drug resistance to one or more drugs 
has increased about 130% in 8 yr in patients not 
previously exposed to anti-tuberculosis drugs (41). 
Previous exposure to drugs is clearly associated 
with drug resistance. The rate of resistance to one or 
more drugs in most series is 9-26% in patients 
without previous treatment and 13-59% in patients 
who have been treated before (8,26,37,4044). Cur- 
rently, resistance to INH is observed in 13-26% of 
patients, and MDRTB, i.e. resistance to at least INH 
and RIF, is found in 3-19% of all patients according 
to recent series (9,14,40,41). 
The importance of MDRTB lies in its poor 
response to available treatment. In HIV-negative 
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subjects, only 5688% of patients show a consistent 
response to treatment, and the relative risk of failure 
of therapy is 80 times higher than in patients with 
susceptible isolates (4446). Furthermore, the relative 
risk of relapse after apparent cure is doubled in 
patients with resistant as compared with susceptible 
bacilli (44,46). 
Multidrug-resistant TB is also strongly associated 
with HIV infection (6,9,47-51). Obviously, immuno- 
suppression is an important factor that facilitates the 
development of TB. Moreover, the high rates of 
infection with HIV in drug addict patients, a group 
with a high prevalence of TB, and their poor adher- 
ence to treatment leading to drug resistance, are also 
factors that have contributed to the propagation of 
MDRTB. Finally, multiple outbreaks of MDRTB 
have been reported in which 20-100% of patients 
involved were infected with HIV (8,9,14,37,52-54). 
Multidrug-resistant TB carries a poor prognosis in 
many cases. In a study, the overall mortality rate in 
patients with MDRTB not infected with HIV was 
37%, with a mortality directly attributable to TB of 
22% (45). The prognosis in AIDS patients with 
MDRTB is dismal: 72-89% of patients will die 
with a median survival time of 4-16 weeks 
(8,14,41,48,55-57). 
Several additional factors should be considered. 
Firstly, the risk for development of TB is 170 times 
higher in patients with AIDS, and 113 times higher in 
HIV-infected patients without AIDS, as compared 
with immunocompetent people (9). Secondly, the 
incidence of TB in patients with AIDS is almost 500 
times the incidence in the general population (58), 
and 3.1 million people are co-infected with HIV and 
M tuberculosis around the world (49). Thirdly, the 
risk for development of TB after a prolonged contact 
with a source case in HIV-infected patients is 37-44% 
in a 5-month period as compared with 2-4% in a I-yr 
period in immunocompetent subjects (9,56,59); and 
the risk for development of active disease in 
tuberculin-positive patients is 7-10% in a 1 -yr period 
in HIV-positive vs. 5-10% in a lifetime in HIV- 
negative subjects (8,9). Finally, HIV infection consti- 
tutes a significant risk factor for clustering in the 
transmission of TB as evidenced by restriction- 
fragment-length polymorphism (RFLP) studies 
(60,61). 
These figures provide an idea of the magnitude of 
the problem, especially among HIV-infected patients, 
and support the urgent necessity of efficient mecha- 
nisms of control. Although additional resources are 
necessary, the extra cost should be compared with the 
enormous health and economic consequences of the 
dissemination of MDRTB. 
Directly Observed Therapy (DOT) 
Generalization of DOT programmes arises as one 
of the measures to undertake in order to ensure 
compliance with anti-tuberculosis therapy. Approxi- 
mately 40% (range 2680%) of the patients do not 
complete a full course of treatment (8,9,16,40,62-66). 
On the contrary, well designed DOT programmes 
have a compliance rate higher than 90% (65,66). 
From an economic point of view, DOT appears to 
be cost-effective. It is considered cheaper than self- 
administered treatment, with saving rates of about 
$51 per patient (67). Furthermore, the cost of treat- 
ment of a patient with MDRTB at a referral hospital 
was estimated to be more than $200 000, the approxi- 
mate cost of DOT for 700 patients (67). Also, the 
case of a patient with MDRTB who transmitted the 
disease to nine friends and relatives has been 
reported. The cost of hospitalization of these patients 
was $950 000 (68). 
Despite the health and economic benefits derived 
from a correct treatment, only lo-15% of the TB 
patients in the U.S. are included in these programmes 
(9,67). However, all patients with MDRTB and those 
with intermittent regimens should be included in 
DOT programmes. Furthermore, DOT should be 
implemented if the rate of non-compliance is higher 
than 10% of unknown (14). Some authors even 
suggest that every patient with TB should receive 
DOT, taking into consideration the cost-effectiveness 
of these programmes as compared with standard 
regimens (67). 
Future Directions 
Since the introduction of RIF more than two 
decades ago, no other major breakthrough in the 
chemotherapy of TB has taken place. The use of 
second-line drugs such as EMB, STM, ethionamide, 
PAS, cycloserine, kanamycin, viomycin, amikacin, 
capreomycin, amithiozone, thiacetazone, rifabutin, 
and clofazimine, among others, can be useful in the 
management of patients with MDRTB while await- 
ing new options. In addition, in the near future the 
role of new drugs such as quinolones, combi- 
nations of /3-lactams and /I-lactamase inhibitors, and 
the newer macrolides in the treatment of TB needs to 
be established. 
However, despite such an array of drugs, none has 
shown or is expected to show a substantially higher 
efficacy than INH, RIF or PZA. Accordingly, other 
drugs active against M tuberculosis are urgently 
needed and every effort should be made to promote 
their investigation, development, and clinical studies 
directed to prove their efficacy. 
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The development of drug delivery systems, con- 
trolled release formulation of anti-tuberculosis drugs, 
liposomal encapsulated drugs, inhibitors of the 
aminoglycoside-modifying enzymes, the use of sub- 
stances directed to increase the mycobacterial cell 
wall permeability, and the evaluation of non- 
antibiotic drugs with activity against M. tuberculosis 
constitute other aspects that merit investigation. 
Improvements in the knowledge of the biology of 
the bacillus, especially from a molecular viewpoint, 
and the identification of genes coding for specific 
enzymatic functions, should lead to the design 
of drugs directed to block crucial biosynthetic 
pathways. 
The development of immunomodulators with the 
capacity to enhance host defence mechanisms and to 
promote the uptake and killing of bacilli could be a 
valuable weapon, especially against intracellular 
organisms. Cytokine therapy, particularly with sub- 
stances that have anti-mycobacterial activity such as 
interleukin-2, granulocyte macrophage colony stimu- 
lating factor, tumour necrosis factor, interferon- 
gamma, and other biological response modifiers, 
could expand the options for treatment especially in 
difficult cases. 
Although its role in the treatment of TB is 
not definitively established, immunotherapy with 
M. vaccae as an adjunct to chemotherapy could be of 
some value particularly preventing relapses caused by 
growth of persisting dormant bacilli. This form of 
combined immunostimulant and chemotherapeutic 
treatment also needs to be thoroughly evaluated. 
Despite these promising advances, the most 
important and applicable measures are a worldwide 
rational use of available drugs, earlier diagnosis and 
immediate treatment of all patients, strict control of 
therapy, and the implementation and generalization 
of DOT programmes. These aspects, along with 
measures for preventing the transmission of TB, 
constitute our main lines of defence against this 
disease. Tuberculosis, the oldest documented infec- 
tious disease which has been affecting mankind for at 
least 7000 yr, is not expected to be eradicated in the 
foreseeable future. 
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